GDTC - CytoMed Therapeutics Limited Ordinary Shares

https://w2.cytomed.sg

Recent News

Singapore-Based CytoMed Therapeutics Stock Dips After SunAct Joins Clinical Trial As Joint Sponsor - CytoMed Therapeutics ( NASDAQ:GDTC )

Benzinga • 8 months, 1 week ago

CytoMed Therapeutics stock surged with 8.37M session volume, surpassing its 22.99K average volume. CytoMed partnered with SunAct for a 5-year Phase 1/2 trial on gamma delta T cells for solid tumor treatment in India. On Monday, CytoMed Therapeutics GDTC stock is down 6.35% at $3.23 at last check ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company is headquartered in Singapore.

52W High

$4.05

52W Low

$1.20

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

-0.36

Valuation

As of 2025-03-31 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-4.45

EV/Revenue (<3 favorable)

355.16

P/S (TTM) (<3 favorable)

44.99

P/B (<3 favorable)

3.25

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

68.86%

Institutions (25–75% balanced)

0.43%

Shares Outstanding

11,733,700

Float

3,593,800

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-03-31 (Overview)

Revenue (TTM)

503,370

Gross Profit (TTM)

472,320

EPS (TTM)

-0.17

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-5.30%

ROE (TTM) (>15% strong)

-0.25%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.25

Momentum

Value

N/A

Trend

—

Signal Cross

No cross

As of

—